BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany.

Research Grants 6 show all


$942.7K
2001

$790.6K
2002

$4.6M
2015

Patents 336show all

  • 104
    A61K - Preparations for medical, dental, or toilet purposes
  • 56
    C12N - Microorganisms or enzymes
  • 37
    C12Y - Enzymes
  • 36
    C07K - Peptides
  • 26
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 24
    C07D - Heterocyclic compounds
  • 8
    A23L - Foods, foodstuffs, or non-alcoholic beverages, not covered by subclasses  -
  • 8
    A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
  • 7
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 6
    Y02A - Technologies for adaptation to climate change

Clinical Trials 221show all

52Phase 344N/A43Phase 219Phase 1/Phase 215Other

SEC Filings show all


262
8-K

62
10-Q

20
10-K

1
S-1

Contact Information

770 Lindaro Street
San Rafael, CA 94901
United States

Overview

Total FundingEmployeesLast Funding DateStatus
1001-5000Ipo